We’re proud to announce a major milestone for both See-Mode Technologies and Antares Ventures: the acquisition of See-Mode by DeepHealth, a subsidiary of RadNet, Inc. (NASDAQ: RDNT), the largest operator of outpatient diagnostic imaging centers in the U.S.
This marks the first exit for Antares Ventures and a powerful validation of our deep-tech investment thesis: backing visionary founders building transformative and impactful technologies in Asia.
See-Mode’s AI-augmented ultrasound reporting platform has been helping clinicians in Australia, Singapore, Canada, and the United States unlock deeper insights from medical images, improving diagnostic accuracy, reducing reporting time, and ultimately driving better patient outcomes. From its initial focus on stroke imaging to its FDA-cleared thyroid and Health Canada-approved breast ultrasound software, See-Mode has consistently turned deep research into practical clinical tools.
At Antares Ventures, our mission is to accelerate deep-tech startups solving real-world problems across Asia’s growth markets and beyond. See-Mode’s journey is a textbook example of this: a company rooted in cutting-edge research and built by founders who understand how to bridge innovation with execution. Healthcare innovation and medtech, in particular, represent some of the most critical frontiers for humanity; whether through precision medicine tailored for emerging markets or next-generation AI-powered clinical tools.
See-Mode, based in Singapore and Australia, exemplifies this intersection of advanced technology and meaningful healthcare outcomes, showing how Asia-based ventures can drive global change. Their acquisition by DeepHealth allows the platform to scale even further, supported by RadNet’s infrastructure and global reach.
Our journey with See-Mode began even before Antares Ventures was founded. In 2018, our Founder and Managing Partner Michael Gryseels made a personal investment in See-Mode and joined as a board observer. When Antares was launched, See-Mode became one of the first companies in our portfolio, and a powerful example of how early conviction and hands-on support can pay off.
Working with founders Dr. Sadaf Monajemi and Dr. Milad Mohammadzadeh has been a privilege. Their complementary expertise in biomedical engineering, AI, and product development, combined with exceptional grit, made them ideal deep-tech partners.
See-Mode started in 2017 as a pre-revenue, pre-product venture navigating complex regulatory and clinical environments. Through strategic execution and persistence, the team secured approvals across five countries, expanded its product suite, and scaled its impact internationally.
This journey also reflects the strength of Antares’ Asia acceleration model: hands-on, patient support designed to help technical founders grow through the region’s unique mix of talent, regulation, and opportunity. Deep-tech demands patient, hands-on support beyond capital, and our model is designed to provide that.
While not Michael’s first exit as an investor, See-Mode’s acquisition marks the first for our fund: A clear example of how our Asia acceleration model helps scale transformative deep-tech into real-world impact.
Antares Ventures’ Founder and Managing Partner, Michael Gryseels, reflects on the journey:
“Investing early in See-Mode was about believing in the founders’ vision and the power of deep tech to transform healthcare. It’s been inspiring to see how their grit and innovation navigated challenges and opportunities in Asia Growth Market to the global market, from product development to regulatory approval. This exit validates not just their work, but also the potential of our Asia acceleration model to scale deep-tech impact globally.”
With regulatory approvals across Australia, New Zealand, Singapore, the U.S., and Canada, See-Mode is well positioned to scale globally. Under RadNet’s DeepHealth, the technology will reach more clinicians and patients, delivering on its mission at greater scale.
We’re proud to have supported See-Mode’s journey from inception to exit, and we remain committed to backing the next wave of deep-tech founders shaping the future of healthcare and beyond.
We invite you to read the original transaction announcement here
